About Charles B. Simone
Excellence in Research
Board Certified in Radiation Oncology
Pleural and Lung Cancer
Simone is known as the leading authority in the use of proton radiation therapies for thoracic malignancies.
He is heavily involved in innovative research and the development of clinical trial strategies with stereotactic body radiation therapy and radiation oncology.
At the New York Proton Center, which is set to open April 2019, he will be working closely with multidisciplinary teams at Mount Sinai Medical Center and Memorial Sloan Kettering Cancer Center.
Both centers previously sent mesothelioma patients out of state if proton therapy was recommended.
Long Career in Maryland
Simone joined the New York Proton Center after serving at the University of Maryland School of Medicine, where he was an associate professor of radiation oncology.
At the UM Greenebaum Cancer Center in Baltimore, Simone was part of a multidisciplinary team that specializes in the diagnosis, treatment and research of mesothelioma and other asbestos-related diseases.
Proton therapy, which is only available at select specialty centers, offers a higher, more precise dose of radiation that eliminates many of the dangerous side effects that often come with traditional radiation.
It reduces the risk to vital organs and nearby tissue, which is especially important for a mesothelioma patient because of the often-vast tumor involvement.
“This is going to be the approach of choice,” Simone said. “We do expect to be busy. This is one of the few centers that can safely treat the entire pleura surface that is often necessary with mesothelioma.”
For years, Simone has been a proponent of patients finding high-volume specialty centers for mesothelioma to receive the best-possible care.
“Going to a high-volume center for oncology makes sense, but particularly for a rare cancer like mesothelioma,” Simone said.
Accomplished Researcher and Author
Simone was the co-author of a recent mesothelioma study that demonstrated how high-volume centers experienced shorter hospital stays, fewer complications and lower three-day readmission rates after surgery than those treated at low-volume centers.
The study, which he published in June of 2018, showed 90-day mortality rates were lower and survival rates higher for those at the high-volume centers.
Before the University of Maryland, Simone worked at the University of Pennsylvania’s Abramson Cancer Center, another high-volume center.
At UPenn, he served as chief of thoracic oncology services and co-director of the Penn Mesothelioma and Pleural Program.
He earned his medical degree from the University of Pennsylvania and did his resident training in radiation oncology at the National Cancer Institute, where he also completed an internship in internal medicine.
Simone used photon and proton radiation therapy in treating patients with various thoracic malignancies at Greenebaum and Abramson.
He has published almost 300 peer-reviewed scientific articles, many of which detail the benefits of proton therapy and its place in a multimodality treatment regimen.
Much of his research is funded by the National Science Foundation, the National Institutes of Health and the Department of Defense.
He also is a member of the National Cancer Institute’s Thoracic Malignancy Steering Committee.
“I look forward to be able to provide patients in New York, the tri-state area and beyond with the very best possible care,” he said.
Disclaimer: Dr. Charles B. Simone has no professional affiliation with Asbestos.com.
3 Cited Article Sources
University of Maryland Greenebaum Comprehensive Cancer Center. (n.d.). Meet the Mesothelioma Team.
Retrieved from: https://www.umms.org/umgccc/cancer-services/cancer-types/mesothelioma/team
University of Maryland School of Medicine. (n.d.). Charles B. Simone, MD.
Retrieved from: http://www.medschool.umaryland.edu/profiles/Simone-Charles/
- University of Maryland Greenebaum Comprehensive Cancer Center. (n.d.). Mesothelioma. Retrieved from: https://www.umms.org/umgccc/cancer-services/cancer-types/mesothelioma
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified March 14, 2019